Joshua Richter, MD, discusses the available combination therapies for patients with early relapsed/refractory multiple myeloma using anti-CD38 monoclonal antibodies.
Joshua Richter, MD, associate professor of medicine, division of hematology and oncology, at the Tisch Cancer Institute, Icahn School of Medicine, and the director of multiple myeloma at the Blavatnik Family-Chelsea Medical Center at Mount Sinai, discusses the available combination therapies for patients with relapsed multiple myeloma.
Defining the different groups of early and late relapse, Richter highlights that therapy would be different for each. In the early relapse setting, the use of an anti-CD38 monoclonal antibody in combination with carfilzomib [Kyprolis] remains the best option. The current anti-CD38 therapies available to combine with carfilzomib are daratumumab [Darzalex] and isatuximab [Sarclisa].
Data supporting these combinations come from the phase 3 CANDOR study (NCT03158688) that showed that patients with relapsed/refractory multiple myeloma maintained their median progression-free survival (PFS) of 28.6 months (95% CI, 22.7–not estimable) compared with patients on carfilzomib alone (HR, 0.59; 95% CI, 0.45-0.78; P < .0001). In the phase 3 IKEMA study (NCT03275285), the addition of the anti-CD38 therapy isatuximab significantly improved PFS for these patients compared with carfilzomib and dexamethasone alone (HR, 0.53; 99% CI, 0.32-0.89; P = .0007). Looking at later-line relapses, Richter highlighted the continuing use of chimeric antigen receptor (CAR) T-cell therapy and novel bispecific antibodies.
Transcription:
0:07 | In general, when we talk about [patients with] relapsed myeloma, we talk about early relapses and late relapses. Early relapse is 1 to 3 prior lines of therapy and late relapses are 4 or more prior lines [of therapy]. And one of the areas that has really dominated the field of early relapse is CD38-based therapy, so daratumumab- and isatuximab-based combinations.
0:30 | Although we can combine these with a variety of therapies, we recognize that CD38 therapy plus Kyprolis has given us some of the most impressive data in the early relapse [setting], specifically with either daratumumab and Kyprolis or isatuximab and Kyprolis. For later line relapses, we're really looking towards the T-cell redirection therapies, like CAR T-cell therapy and bispecific antibodies.
Leslie Reviews Relevant Data for Treatment of Relapsed/Refractory CLL
May 8th 2024During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.
Read More
Key Takeaways From QOL and Use of Steroids With IO-Based RCC Regimens
May 6th 2024During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the safety and quality-of-life data for ipilimumab plus nivolumab in patients with advanced renal cell carcinoma in the second article of a 2-part series.
Read More
NGS and ctDNA Considered in Advanced Breast Cancer After Progression
May 3rd 2024During a Case-Based Roundtable® event, Ruth M. O'Regan, MD, led a discussion on whether to order next-generation sequencing and/or circulating tumor DNA testing for a patient with hormone receptor–positive breast cancer after progression in the first article of a 2-part series.
Read More
Comparing Choices for IO/TKI Combinations in Advanced RCC
May 2nd 2024During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on the combination of immunotherapy and tyrosine kinase inhibitors for patients with advanced renal cell carcinoma in the second article of a 2-part series.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More